"Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up" (vol 29, pg no 918-923, 2023)

被引：0

作者：

Barda, Noam ^{[1
,2
,3
]}

Lustig, Yaniv ^{[4
,5
]}

Indenbaum, Victoria ^{[4
,5
]}

Zibly, Daniel ^{[6
]}

Joseph, Gili

Asraf, Keren ^{[4
]}

Weiss-Ottolenghi, Yael ^{[4
,6
]}

Amit, Sharon ^{[4
,8
]}

Kliker, Limor ^{[4
,5
]}

Abu-Kadar, Bian ^{[4
,5
]}

Ben-Ami, Eytan ^{[9
]}

Canetti, Michal ^{[4
,6
,9
]}

Koren, Ravit ^{[5
]}

Katz-Likvornik, Shiri ^{[5
]}

Halpern, Osnat ^{[5
]}

Mendelson, Ella ^{[4
,5
]}

Doolman, Ram ^{[7
]}

Harats, Dror ^{[4
,10
]}

Kreiss, Yitshak ^{[4
,10
]}

Mandelboim, Michal ^{[4
,5
]}

Regev-Yochay, Gili ^{[4
,6
,11
]}

机构：

[1] Sheba Med Ctr, ARC Innovat Ctr, Tel Hashomer, Ramat Gan, Israel

[2] Ben Gurion Univ Negev, Software & Informat Syst Engn, Beer Sheva, Israel

[3] Ben Gurion Univ Negev, Epidemiol Biostat & Community Hlth Serv, Beer Sheva, Israel

[4] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[5] Minist Hlth, Publ Hlth Serv, Cent Virol Lab, Ramat Gan, Israel

[6] Sheba Med Ctr, Infect Prevent & Control Unit, Ramat Gan, Israel

[7] Sheba Med Ctr, Dworman Automated Mega Lab, Ramat Gan, Israel

[8] Sheba Med Ctr, Clin Microbiol, Ramat Gan, Israel

[9] Sheba Med Ctr, Phase Clin Trials Unit 1, Ramat Gan, Israel

[10] Sheba Med Ctr, Gen Management, Ramat Gan, Israel

[11] Sheba Med Ctr, Ramat Gan, Israel

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1016/j.cmi.2023.12.015

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：409 / 413

页数：5

共 25 条

[21] Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022)
Liu, Xinxue
Munro, Alasdair P. S.
Feng, Shuo
Janani, Leila
Aley, Parvinder K.
Babbage, Gavin
Baxter, David
Bula, Marcin
Cathie, Katrina
Chatterjee, Krishna
Dejnirattisai, Wanwisa
Dodd, Kate
Enever, Yvanne
Qureshi, Ehsaan
Goodman, Anna L.
Green, Christopher A.
Harndahl, Linda
Haughney, John
Hicks, Alexander
Klaauw, Agatha A. van der
Kwok, Jonathan
Libri, Vincenzo
Llewelyn, Martin J.
McGregor, Alastair C.
Minassian, Angela M.
Moore, Patrick
Mughal, Mehmood
Mujadidi, Yama
Holliday, Kyra
Osanlou, Orod
Osanlou, Rostam
Owens, Daniel R.
Pacurar, Mihaela
Palfreeman, Adrian
Pan, Daniel
Rampling, Tommy
Regan, Karen
Saich, Stephen
Serafimova, Teona
Saralaya, Dinesh
Screaton, Gavin R.
Sharma, Sunil
Sheridan, Ray
Sturdy, Ann
Supasa, Piyada
Thomson, Emma C.
Todd, Shirley
Twelves, Chris
Read, Robert C.
Charlton, Sue
JOURNAL OF INFECTION, 2023, 86 (05) : 540 - 541
[22] Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Liu, Xinxue
Munro, Alasdair P. S.
Feng, Shuo
Janani, Leila
Aley, Parvinder K.
Babbage, Gavin
Baxter, David
Bula, Marcin
Cathie, Katrina
Chatterjee, Krishna
Dejnirattisai, Wanwisa
Dodd, Kate
Enever, Yvanne
Qureshi, Ehsaan
Goodman, Anna L.
Green, Christopher A.
Harndahl, Linda
Haughney, John
Hicks, Alexander
van der Klaauw, Agatha A.
Kwok, Jonathan
Libri, Vincenzo
Llewelyn, Martin J.
McGregor, Alastair C.
Minassian, Angela M.
Moore, Patrick
Mughal, Mehmood
Mujadidi, Yama F.
Holliday, Kyra
Osanlou, Orod
Osanlou, Rostam
Owens, Daniel R.
Pacurar, Mihaela
Palfreeman, Adrian
Pan, Daniel
Rampling, Tommy
Regan, Karen
Saich, Stephen
Serafimova, Teona
Saralaya, Dinesh
Screaton, Gavin R.
Sharma, Sunil
Sheridan, Ray
Sturdy, Ann
Supasa, Piyada
Thomson, Emma C.
Todd, Shirley
Twelves, Chris
Read, Robert C.
Charlton, Sue
JOURNAL OF INFECTION, 2022, 84 (06) : 795 - 813
[23] The effectiveness of a program of physical activity and diet to modify cardiovascular risk factors in patients with severe mental illness after 3-month follow-up: CAPiCOR randomized clinical trial (vol 30, pg 1028, 2015)
Masa-Font, R.
Fernandez-San-Martin, M. I.
Martin Lopez, L. M.
Alba Munoz, A. M.
Oller Canet, S.
Martin Royo, J.
San Emeterio Echevarria, L.
Olona Tabuena, N.
Ibarra Jato, M.
Barroso Garcia, A.
Gonzalez Tejon, S.
Tajada Vitales, C.
Diaz Mujica, B.
Vinas Cabrera, L.
Sanchis Catalan, R.
Salvador Barbarroja, T.
EUROPEAN PSYCHIATRY, 2017, 41 : E1 - E1
[24] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
Ella, Raches
Reddy, Siddharth
Jogdand, Harsh
Sarangi, Vamshi
Ganneru, Brunda
Prasad, Sai
Das, Dipankar
Raju, Dugyala
Praturi, Usha
Sapkal, Gajanan
Yadav, Pragya
Reddy, Prabhakar
Verma, Savita
Singh, Chandramani
Redkar, Sagar Vivek
Gillurkar, Chandra Sekhar
Kushwaha, Jitendra Singh
Mohapatra, Satyajit
Bhate, Amit
Rai, Sanjay
Panda, Samiran
Abraham, Priya
Gupta, Nivedita
Ella, Krishna
Bhargava, Balram
Vadrevu, Krishna Mohan
LANCET INFECTIOUS DISEASES, 2021, 21 (07): : 950 - 961
[25] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial (vol 24, pg 989, 2023)
Ozguroghu, M.
Kilickap, S.
Sezer, A.
LANCET ONCOLOGY, 2023, 24 (10): : e405 - e405

← 1 2 3 →